Back
 JBM  Vol.5 No.8 , August 2017
Evaluation of Adverse Events Following Immunization against Rotavirus Regardless of Recommended Age Restriction
Abstract: Introduction: Mild and moderate Adverse Events Following Immunization (AEFI) against Rotavirus has not received much attention when the vaccine is administered regardless of recommended age restriction. Objectives: To describe the behavior of mild and moderate AEFI in immunized subjects against Rotavirus, in who age restriction period had not been considered. Methods: A case-control study in which we included immunized patients with monovalent oral vaccine against rotavirus and divided them into two groups: 1) Infants who received RV1 vaccine without considering the recommended period, and 2) Infants who were vaccinated with the recommended schedule. Results: From the total doses, 143/1894 (7.5%) were administered outside the restriction period. The most frequent AEFIs with the first dose were purpura, polypnea, and rhinorrhea; For the second dose: purpura, bloody stools, irritability and rhinorrhea. Conclusions: This study shows the benefits from vaccination regardless of age restriction are more beneficial compared to the possible risks of AEFI.
Cite this paper: Reyna-Figueroa, J. , Bercholc-Urinowsky, I. , Cardoso-Yah, G. , Vazquez-Alvarado, R. , Ramos-López, D. , Campos-Romero, F. , Handelsman, C. and Limón-Rojas, A. (2017) Evaluation of Adverse Events Following Immunization against Rotavirus Regardless of Recommended Age Restriction. Journal of Biosciences and Medicines, 5, 78-82. doi: 10.4236/jbm.2017.58006.
References

[1]   Richardson, V., Hernandez, J., Quintanar, M., Esparza, M., Johnson, B. and Gomez, C. (2010) Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico. The New England Journal of Medicine, 362, 299-305.
https://doi.org/10.1056/NEJMoa0905211

[2]   Fernandes, E.G., Leshem, E., Patel, M., Flannery, B., Pellini, A.C., Veras, M.A. and Sato, H.K. (2016) Hospital-Based Surveillance of Intussusception among Infants. Journal de Pediatrics, 92, 181-187.
https://doi.org/10.1016/j.jped.2015.06.008

[3]   Black, S. (2015) The Costs and Effectiveness of Large Phase III Pre-Licensure Vaccine Clinical Trials. Expert Review of Vaccines, 14, 1543-1548.
https://doi.org/10.1586/14760584.2015.1091733

[4]   Armah, G., Pringle, K., Enweronu-Laryea, C.C., Ansong, D., Mwenda, J.M., Diamenu, S.K., Narh, C., Lartey, B., Binka, F., Grytdal, S., Patel, M., Parashar, U. and Lopman, B. (2016) Impact and Effectiveness of Monovalent Rotavirus Vaccine against Severe Rotavirus Diarrhea in Ghana. Clinical Infectious Diseases, 62, S200-207. https://doi.org/10.1093/cid/ciw014

[5]   WHO (2009) Rotavirus Vaccines: An Update. The Weekly Epidemiological Record, 84, 533-540.

[6]   Patel, M.M., Clark, A.D., Sanderson, C.F.B., Tate, J. and Parashar, U.D. (2012) Removing the Age Restrictions for Rotavirus Vaccination: A Benefit-Risk Modeling Analysis. PLOS Medicine, 9, e1001330.
https://doi.org/10.1371/journal.pmed.1001330

[7]   Reyna, F.J., Vidal, R.P. and Richardson, L.C.V. (2011) Inmunización contra rotavirus con vacuna oral monovalente. Revista de Investigación Clínica, 63, 391-398.

[8]   Yen, C., Figueroa, J., Uribe, E., Carmen-Hernández, L., Tate, J., Parashar, U., et al. (2011) Monovalent Rotavirus Vaccine Provides Protection Against an Emerging Fully Heterotypic G9P [4] Rotavirus Strain in Mexico. The Journal of Infectious Diseases, 204, 783-786.

[9]   Ndeffo Mbah, M.L., Liu, J., Bauch, C.T., Tekel, Y.I., Medlock, J., et al. (2012) The Impact of Imitation on Vaccination Behavior in Social Contact Networks. PLOS Computational Biology, 8, e1002469. https://doi.org/10.1371/journal.pcbi.1002469

[10]   Patel, M.M., Lopez-Collada, V.R., Bulhoes, M.M., De Oliveira, L.H., Bautista, M.A., et al. (2011) Intussusception Risk and Health Benefits of Rotavirus Vaccination in Mexico and Brazil. New England Journal of Medicine, 364, 2283-2292.
https://doi.org/10.1056/NEJMoa1012952

[11]   Raebel, M.A. and Ou, B.S. (1999) Rotavirus Disease and Its Prevention in Infants and Children. Pharmacotherapy, 19, 1279-1295.
https://doi.org/10.1592/phco.19.16.1279.30875

[12]   Patel, M.M., Clark, A.D., Glass, R.I., Greenberg, H., Tate, J., et al. (2009) Broadening the Age Restriction for Initiating Rotavirus Vaccination in Regions with High Rotavirus Mortality: Benefits of Mortality Reduction versus Risk of Fatal Intussusception. Vaccine, 27, 2916-2922.
https://doi.org/10.1016/j.vaccine.2009.03.016

 
 
Top